Top

The European Journal of Health Economics

Published in:

01-06-2006 | Commentary

A taxonomy of health utility assessment methods and the role for uncertainty analysis

Authors: Agota Szende, Caroline Schaefer

Published in: The European Journal of Health Economics | Issue 2/2006

Excerpt

The evaluation of health benefits in terms of quality-adjusted life years (QALYs) has become a widely applied approach in research and health-care decision making. Yet, health utility assessment methods, which inform QALY calculations, are far from uniform. One important aspect that distinguishes utility assessment methods is the different degree to which they rely on descriptive systems, predictive algorithms and extrapolation to assign utility values to health states. …

El-Dika S, Guyatt GH, Armstrong D, Degl’innocenti A, Wiklund I, Fallone CA, Tanser L, Veldhuyzen van Zanten S, Heels-Ansdell D, Wahlqvist P, Chiba N, Barkun AN, Austin P, Schunemann HJ (2005) The impact of illness in patients with moderate to severe gastro-esophageal reflux disease. BMC Gastroenterol 5:23CrossRefPubMed

Feeny D, Furlong W, Saigal S, Sun J (2004) Comparing directly measured standard gamble scores to HUI2 and HUI3 utility scores: group- and individual-level comparisons. Soc Sci Med 58:799–809CrossRefPubMed

Secnik K, Matza LS, Cottrell S, Edgell E, Tilden D, Mannix S (2005) Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United Kingdom. Med Decis Making 25:56–70CrossRefPubMed

Sherman KE, Sherman SN, Chenier T, Tsevat J (2004) Health values of patients with chronic hepatitis C infection. Arch Intern Med 164:2377–2382CrossRefPubMed

McCabe CJ, Stevens KJ, Brazier JE (2005) Utility scores for the Health Utilities Index mark 2: an empirical assessment of alternative mapping functions. Med Care 43:627–635CrossRefPubMed

Shaw JW, Johnson JA, Coons SJ (2005) US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 43:203–220CrossRefPubMed

Beusterien K, Leigh N, Jackson C, Miller R, Mayo K, Revicki D (2005) Integrating preferences into health status assessment for amyotrophic lateral sclerosis: the ALS Utility Index. Amyotroph Lateral Scler Other Motor Neuron Disord 6:169–176PubMed

Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A (1998) Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 114:998–1007PubMed

Brazier J, Roberts J, Deverill M (2002) The estimation of a preference based measure of health from the SF-36. J Health Econ 21:271–292CrossRefPubMed

10.

Lenert LA, Sturley AP, Rapaport MH, Chavez S, Mohr PE, Rupnow M (2004) Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 71:155–165CrossRefPubMed

11.

Longworth L, Buxton MJ, Sculpher M, Smith DH (2005) Estimating utility data from clinical indicators for patients with stable angina. Eur J Health Econ 6:347–353CrossRefPubMed

12.

MVH Group (1995) The measurement and valuation of health. Final report on the modelling of valuation tariffs. Centre for Health Economics: York

13.

Dolan P (1997) Modeling valuations for EuroQol health states. Med Care 35:1095–1108CrossRefPubMed

Title: A taxonomy of health utility assessment methods and the role for uncertainty analysis
Authors: Agota Szende
Caroline Schaefer
Publication date: 01-06-2006
Publisher: Springer-Verlag
Published in: The European Journal of Health Economics / Issue 2/2006
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-005-0334-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A taxonomy of health utility assessment methods and the role for uncertainty analysis

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 2/2006

The future of imaging techniques for cancer patients in The Netherlands

Pharmaceutical policy in Italy

Health care and patients’ migration across Spanish regions

Cost-effectiveness of memantine in community-based Alzheimer’s disease patients: an adaptation in Spain

Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers

Choices and utilization in dental care